Akèy › Kansè nan tete › Illinois › Chicago
Etid klinik pou Kansè nan tete nan Chicago, IL
58 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Chicago (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Ap rekriteFaz 3
- Affiliated Oncologists IL, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- ak 1 plis
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- University of Illinois Cancer Center, Chicago
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Ap rekriteFaz 2
- University of Illinois Cancer Center, Chicago
- The University of Chicago, Chicago
PRE-ISPY Phase I/II Oncology Platform Program
Ap rekriteFaz 1/2
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment
Ap rekrite
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Ap rekriteFaz 3
- Rush University Medical Center ( Site 0079), Chicago
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Ap rekriteFaz 3
- Research Site, Chicago
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Ap rekrite
- Northwestern University, Chicago
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- City of Hope, Chicago, Chicago
- Northwestern Memorial Hospital, Chicago
- University of Illinois at Chicago, Chicago
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
Ap rekriteVolontè an sante akeyi
- University of Chicago, Chicago
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Ap rekriteFaz 1/2
- University of Illinois Hospital & Health Sciences System, Chicago
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- Northwestern Memorial Hospital, Chicago
- RUSH MD Anderson Cancer Center, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- University of Chicago, Chicago
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Ap rekriteFaz 1/2
- Northwestern University, Chicago
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Ap rekriteFaz 2
- Northwestern University, Chicago
- Rush University Medical Center, Chicago
- University of Chicago, Chicago
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Ap rekriteFaz 3
- Rush University Medical Center, Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Ap rekriteFaz 2
- University of Illinois Cancer Center, Chicago
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- Mount Sinai Hospital Medical Center, Chicago
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- ak 4 plis
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Ap rekriteFaz 3
- Northwestern University, Chicago
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
Ap rekriteVolontè an sante akeyi
- University Of Chicago Medicine Comprehensive Cancer Center, Chicago
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Ap rekriteFaz 2
- University of Chicago Medical Center, Chicago
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Ap rekriteFaz 2
- Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
Ap rekriteFaz 2
- University of Illinois, Chicago
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Ap rekriteFaz 2
- The University of Chicago Medical Center, Chicago
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- Northwestern University, Chicago
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Chicago
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Ap rekriteFaz 2/3
- Local Institution - 0280, Chicago
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Ap rekriteFaz 3
- Northwestern University - Northwestern Memorial Hospital, Chicago
E-Mindfulness Approaches for Living After Breast Cancer
Ap rekriteFaz 3
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Ap rekriteFaz 2
- Northwestern University, Chicago
- University of Illinois College of Medicine - Chicago, Chicago
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
Ap rekriteFaz 4
- University of Illinois, Chicago
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
Ap rekriteFaz 2
- Northwestern University, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Ap rekriteFaz 1/2
- Northwestern University, Chicago
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
Ap rekriteFaz 2
- University of Illinois Cancer Center, Chicago
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Ap rekriteFaz 1
- University of Chicago Comprehensive Cancer Center, Chicago
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Ap rekriteFaz 2
- University of Chicago, Chicago
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Ap rekriteFaz 2
- Northwestern University, Chicago
Feasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer.
Ap rekrite
- Robert H. Lurie Comprehensive Cancer Center, Chicago
- University of Illinois Chicago, Chicago
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Ap rekriteFaz 2
- University of Chicago Medical Center, Chicago
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- Rush MD Anderson Cancer Center, Chicago
- ak 2 plis
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Ap rekriteFaz 1
- Northwestern Memorial Hospital, Chicago
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
Ap rekriteFaz 2
- University of Chicago, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- University of Chicago Medical Center, Chicago
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- John H Stroger Jr Hospital of Cook County, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care
Ap rekrite
- University of Illinois, Chicago
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Ap rekriteFaz 2
- University of Chicago Medical Center, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- The University of Chicago Comprehensive Cancer Center, Chicago
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Ap rekriteFaz 4
- University of Chicago Medical Center, Chicago
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Ap rekriteEtid obsèvasyon
- Rush Cancer Center, Chicago
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
Ap rekriteFaz 2
- University of Illinois, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Chicago
Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer
Ap rekriteEtid obsèvasyon
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Ap rekriteFaz 3
- John H Stroger Jr Hospital of Cook County, Chicago
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Ap rekriteFaz 1
- University of Chicago Medical Center, Chicago
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Ap rekriteEtid obsèvasyon
- University of Illinois at Chicago, Chicago
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
Etid Kansè nan tete nan lòt vil
- New York City, NY134 etid
- Houston, TX126 etid
- Boston, MA111 etid
- Nashville, TN80 etid
- Los Angeles, CA72 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Durham, NC63 etid
- Queens, NY63 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
- Baltimore, MD47 etid
Lòt etid nan Chicago
- Kansè Poumon ki pa ti selil61 etid
- Kansè (tout kalite)51 etid
- Kansè Metastatik45 etid
- Kansè pwostat45 etid
- Obèsite41 etid
- Kansè poumon41 etid
- Kansè ovè36 etid
- Akidan serebavaskilè34 etid
- Kansè kolorektal33 etid
- Ensifizyans kadyak31 etid
- Sipwa28 etid
- Karsinòm selil skuamèz tèt ak kou26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.